-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The researchers published their results in the journal Cell, showing that patients with colorectal cancer tend to have significantly reduced ILC3s and functional changes
What is colorectal cancer?
Colorectal cancer is a disease in which cells in the colon or rectum grow out of control
Colorectal cancer is the fourth most common cancer in the United States, with approximately 150,000 new cases and approximately 50,000 deaths each year
"These findings provide new possibilities for the clinical treatment of colorectal cancer, and also help explain why this type of cancer often does not respond to immunotherapy," said senior author Dr.
One factor that affects the resistance of immunotherapy may be the intestinal microbiota, the number of bacteria and other microbial species in the intestine, which usually help digestion, support various metabolic functions, and play a role in regulating the immune system
ILC3s are present in the intestinal tract and are thought to help regulate the relationship between the immune system and intestinal microbes
The 3 groups of intrinsic lymphoid cells usually play a key role in maintaining a healthy dialogue between the gut microbiota and the immune environment
"This is an exciting discovery, and it may have a broad impact on our understanding of the pathogenesis, progression, and treatment response of gastrointestinal malignancies," said Dr.
In the loss of the normal activity of ILC3 in the intestine, the authors further observed that the ability of ILC3 to regulate a specific subset of immune cells called T cells was significantly disrupted
The researchers said that these common results have a major impact on the development of tumors
Finally, in the colon biopsy of patients with inflammatory bowel disease (IBD), the researchers found ILC3s-related abnormalities similar to those in patients with colorectal cancer
"A better understanding of the contribution of the microbiome to cancer development and treatment response can revolutionize patient management strategies
"Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer" by Jeremy Goc, Mengze Lv, Nicholas J.
